Hemolytic Uremic Syndrome (HUS) Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Alnylam Initiates Phase 2 Clinical Study of Cemdisiran (ALN-CC5) in Patients with Atypical Hemolytic-Uremic Syndrome (aHUS)
CAMBRIDGE, Mass.--(BUSINESS WIRE) September 26, 2017 -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has initiated a Phase 2 clinical study with cemdisiran (formerly known as ALN-CC5),... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 26, 2017 Category: Pharmaceuticals Source Type: clinical trials

Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)
Condition: Atypical Hemolytic Uremic Syndrome (aHUS) Intervention: Biological: ALXN1210 Sponsor: Alexion Pharmaceuticals Not yet recruiting - verified April 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 24, 2017 Category: Research Source Type: clinical trials